依达拉奉联合巴曲酶治疗急性脑梗死的疗效观察

Observation of curative effects of Edaravone combining Batroxobin on treating acute cerebral infarction

目的观察依达拉奉联合巴曲酶治疗急性脑梗死(ACI)的疗效。方法 86例ACI患者随机分为依达拉奉+巴曲酶治疗(联合治疗)组和巴曲酶组。在常规及巴曲酶治疗的基础上,联合治疗组给予依达拉奉30mg静脉滴注,每日2次,连用14d;两组分别于治疗前、治疗后7d、14d行神经功能缺损程度评分(NDS);治疗前及治疗后5d、10d、14d检查血液流变学及凝血指标。结果治疗后第7d及第14d两组NDS较治疗前显著降低(P<0.05～0.01);联合治疗组治疗14d时NDS明显低于巴曲酶组(P<0.01)。两组治疗第5d和第10d时纤维蛋白原含量及全血低切黏度较治疗前显著下降(均P<0.01);联合治疗组显效率(69.8%)和总有效率(95.3%)显著高于巴曲酶组(46.5%、79.1%)(均P<0.05)。结论依达拉奉联合巴曲酶治疗ACI疗效优于单用巴曲酶。

Objective To observe the curative effects of Edaravone combining Batroxobin on treating acute cerebral infarction （ACI）.Methods 86 patients with ACI were randomly divided into Edaravone＋Batroxobin（united treatment）group and Batroxobin group. At the basic of routine and Batroxobin therapy,the united treatment group received Edaravone 30 mg intravenous infusion,twice a day for 14 d. Neurological deficit scale（NDS）was examined before and 7 d,14 d after treatment; the indexes of hemorheology and blood coagulation were examined before and 5 d,10 d,14 d after treatment in both groups.Results 7 d,14 d after treatment,the NDS of both groups were significantly decreased than those before treatment（P0.05-0.01）. 14 d after treatment,the NDS of the united treatment group were significantly lower than that in the Batroxobin group （P0.01）. The levels of fibrinogen and whole blood viscosity （low cuts） were extremely decreased on 5 d,10 d after treatment than those before treatment in both groups （all P0.01）. The obvious effective rate （69.8%） and the general effective rate （95.3%） in the united treatment group were obviously higher than those in the Batroxobin group （46.5%,79.1%） （all P0.05）.Conclusion Edaravone combining Batroxobin are more effective than Batroxobin only treatment for ACI.